increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMmaprotiline increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.bazedoxifene/conjugated estrogensbazedoxifene/conjugated estrogens, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.brimonidinemaprotiline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.butabarbitalbutabarbital, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.butalbitalbutalbital, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.carbamazepinecarbamazepine decreases levels of maprotiline by increasing metabolism. Minor/Significance Unknown.chloroquinechloroquine increases toxicity of maprotiline by QTc interval. Minor/Significance Unknown.chlorpromazinemaprotiline, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, chlorpromazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.chlorpropamidemaprotiline increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.conjugated estrogensconjugated estrogens, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.conjugated estrogens, vaginalconjugated estrogens, vaginal, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.desfluranedesflurane, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.dexmethylphenidatedexmethylphenidate increases effects of maprotiline by decreasing metabolism. Minor/Significance Unknown.estradiolestradiol, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticestrogens conjugated synthetic, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estropipateestropipate, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.etomidateetomidate, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.eucalyptusmaprotiline and eucalyptus both increase sedation. Minor/Significance Unknown.fluphenazinemaprotiline, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.glimepiridemaprotiline increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizidemaprotiline increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburidemaprotiline increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin aspartmaprotiline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirmaprotiline increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glarginemaprotiline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisinemaprotiline increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lispromaprotiline increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHmaprotiline increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humanmaprotiline increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoproterenolisoproterenol, maprotiline. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.ketamineketamine, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.lithiumlithium, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.mestranolmestranol, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metforminmaprotiline increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.miglitolmaprotiline increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.nateglinidemaprotiline increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of maprotiline by pharmacodynamic synergism. Minor/Significance Unknown.pentobarbitalpentobarbital, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazinemaprotiline, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.pioglitazonemaprotiline increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of maprotiline by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.primidoneprimidone, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazinemaprotiline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazinemaprotiline, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazinemaprotiline, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.repaglinidemaprotiline increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.rosiglitazonemaprotiline increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.sagemaprotiline and sage both increase sedation. Minor/Significance Unknown.saxagliptinmaprotiline increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.secobarbitalsecobarbital, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.serdexmethylphenidate/dexmethylphenidateserdexmethylphenidate/dexmethylphenidate increases effects of maprotiline by decreasing metabolism. Minor/Significance Unknown.sevofluranesevoflurane, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.sitagliptinmaprotiline increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.sulfamethoxazolesulfamethoxazole decreases levels of maprotiline by unspecified interaction mechanism. Minor/Significance Unknown.thioridazinemaprotiline, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.tolazamidemaprotiline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamidemaprotiline increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.trifluoperazinemaprotiline, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.vasopressinmaprotiline increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.verapamilverapamil increases levels of maprotiline by decreasing metabolism. Minor/Significance Unknown.vildagliptinmaprotiline increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.zolpidemzolpidem, maprotiline. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.5-HTPMonitor Closely (1)maprotiline and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abirateroneMonitor Closely (1)abiraterone increases levels of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of maprotiline by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .acarboseMinor (1)maprotiline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)aclidinium and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.acrivastineMonitor Closely (1)acrivastine and maprotiline both increase sedation. Use Caution/Monitor.adagrasibSerious - Use Alternative (1)adagrasib, maprotiline. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.albuterolMonitor Closely (2)maprotiline increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. albuterol and maprotiline both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)maprotiline, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.alfentanilMonitor Closely (1)alfentanil and maprotiline both increase sedation. Use Caution/Monitor.alfuzosinMonitor Closely (2)maprotiline and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and maprotiline both increase QTc interval. Use Caution/Monitor.almotriptanMonitor Closely (1)almotriptan and maprotiline both increase serotonin levels. Modify Therapy/Monitor Closely.alprazolamMonitor Closely (1)alprazolam and maprotiline both increase sedation. Use Caution/Monitor.amiodaroneSerious - Use Alternative (1)maprotiline and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideSerious - Use Alternative (1)maprotiline and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amitriptylineMonitor Closely (2)amitriptyline and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor. amitriptyline and maprotiline both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amitriptyline and maprotiline both increase QTc interval. Avoid or Use Alternate Drug. amitriptyline and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.amobarbitalMonitor Closely (1)amobarbital and maprotiline both increase sedation. Use Caution/Monitor.Minor (1)amobarbital, maprotiline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.amoxapineMonitor Closely (2)amoxapine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor. amoxapine and maprotiline both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amoxapine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug. amoxapine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.anagrelideSerious - Use Alternative (1)anagrelide and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.anticholinergic/sedative combosMonitor Closely (1)anticholinergic/sedative combos and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.apomorphineMonitor Closely (1)maprotiline and apomorphine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)apomorphine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.arformoterolMonitor Closely (2)maprotiline increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. arformoterol and maprotiline both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)maprotiline, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.aripiprazoleMonitor Closely (1)aripiprazole and maprotiline both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)aripiprazole and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.armodafinilMonitor Closely (1)maprotiline increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arsenic trioxideSerious - Use Alternative (1)maprotiline and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemetherMonitor Closely (1)artemether and maprotiline both increase QTc interval. Use Caution/Monitor.artemether/lumefantrineSerious - Use Alternative (1)maprotiline and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.asenapineMonitor Closely (1)asenapine and maprotiline both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)asenapine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalMonitor Closely (1)asenapine transdermal and maprotiline both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)asenapine transdermal and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.atazanavirMonitor Closely (1)atazanavir increases levels of maprotiline by unspecified interaction mechanism. Use Caution/Monitor.atomoxetineMonitor Closely (1)atomoxetine and maprotiline both increase QTc interval. Use Caution/Monitor.atracuriumMonitor Closely (1)atracurium and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineMonitor Closely (1)atropine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.Minor (1)maprotiline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMMonitor Closely (1)atropine IV/IM and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.Minor (1)maprotiline increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.avapritinibMonitor Closely (1)avapritinib and maprotiline both increase sedation. Use Caution/Monitor.azelastineMonitor Closely (1)azelastine and maprotiline both increase sedation. Use Caution/Monitor.azithromycinMonitor Closely (1)maprotiline and azithromycin both increase QTc interval. Use Caution/Monitor.baclofenMonitor Closely (1)baclofen and maprotiline both increase sedation. Use Caution/Monitor.bazedoxifene/conjugated estrogensMinor (1)bazedoxifene/conjugated estrogens, maprotiline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.bedaquilineMonitor Closely (1)maprotiline and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsMonitor Closely (1)belladonna alkaloids and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumMonitor Closely (2)belladonna and opium and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor. belladonna and opium and maprotiline both increase sedation. Use Caution/Monitor.benperidolMonitor Closely (1)benperidol and maprotiline both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenMonitor Closely (1)benzhydrocodone/acetaminophen, maprotiline. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of